Session I

Genomic landscapes

Genomic analysis of CLL
K. Ridout
Genetic portrait of CLL: insights from mouse models
D. Efremov
Trafficking of CLL cells to and from microenvironmental niche
C. Pepper
Mechanism of epigenetic dynamics/evolution
D. Rossi
Perspectives of clonal evolution at the single-cell level
S. Gohil
Session II

Richter syndrome

Biology
D. Rossi
Novel approaches of treatment
S. Deaglio
Session III

Spectrum of CLL disease and new insights

MBL: low versus high count
A. Orfao
New development of prognostic scoring systems
D. Rossi
Session IV

Targeted therapies

Ibrutinib
S. O’Brien
Venetoclax
C. Tam
Acalabrutinib
M.S. Davids
Session V

Few intriguing questions

Is there a place for the new version of Fludarabine-containing regimen?
M.S. Davids
Is there already a role for CAR-T therapy?
S. Siddiqi
Session VI

Doublet, triplet: is this the potential future of BTKi plus BCL2i?

Ibrutinib plus Venetoclax
C. Tam
Acalabrutinib plus Venetoclax
M.S. Davids
Session VIII

Interesting observations

Selecting the appropriate BTKi for frontline treatment
M.S. Davids
Role of Venetoclax in patients with high risk CLL
C. Tam
Selecting the appropriate BTKi in the treatment of relapsed CLL
S. O’Brien
Development of resistance to BCL2 inhibition
P. Sportoletti
Development of resistance to Pirtobrutinib
C. Tam
Privacy Policy | Cookie Policy